多地新版“惠民保”产品扩容，衔接丙类药品目录如何做？

Core Viewpoint - The continuous operation of the Huiminbao products is increasingly focused on supporting innovative drugs and medical devices, as well as expanding health management services to enhance accessibility and sustainability [1][3]. Group 1: Huiminbao Product Developments - Multiple regions, including Anhui, Shenzhen, and Shanghai, have launched their 2025 versions of Huiminbao products, offering new insurance options to local residents [2]. - Shenzhen Huiminbao has added several innovative treatments, including proton heavy ion therapy and robotic surgery, while Shanghai's "Huibao" has expanded its list of special drugs from 41 to 48, including a new CAR-T therapy [2][3]. - Anhui Huiminbao has introduced more health management services, such as dental services and cancer screening, to meet diverse health needs [2][4]. Group 2: Innovative Drug and Device Inclusion - The inclusion of innovative drugs and devices in Huiminbao is guided by principles of affordability, effectiveness, and encouragement of technological innovation [4][5]. - Companies seeking to have their products included in Huiminbao must demonstrate significant contributions to existing treatment methods and engage in innovative payment models to mitigate budget impacts [5][6]. Group 3: Integration with Class B Drug Directory - The integration of Huiminbao with the Class B drug directory is expected to streamline negotiations between insurance and pharmaceutical companies, enhancing the efficiency of innovative drug coverage [6][7]. - Challenges exist in aligning the interests of different insurance companies and ensuring effective data sharing for risk assessment and pricing [7][8]. - Continuous communication with health insurance departments and standardization of coverage and claims processes are essential for improving service levels across Huiminbao products [8].